Biotechnology Value Fund — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Executive Officer, Director)inDavid Schaffer(Director)inTheresa Janke(Executive Officer)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityChiesi VenturesPappas CapitalPfizer Venture Investments+3 more
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Chief Executive Officer, Founder)
BoardIvan Trifunovich(Director)John Wesley(Director)
Co-investors8VCAisling CapitalMission Bay CapitalMission BiocapitalOlive Tree CapitalSR One Capital Management+3 more
BiotechFremont, US
Avanish Vellanki(Executive Officer)in
Co-investorsJanus Henderson InvestorsSamsara BioCapital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.